Multiparametric magnetic resonance imaging in diagnosis of local prostate cancer recurrence after radiation therapy and radical prostatectomy: a unified PI-RR reporting system

2023

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.17650/1726-9776-2023-19-4-61-76
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Multiparametric magnetic resonance imaging (mpMRI) has an indisputable advantage in diagnosis of local recurrences of prostate cancer (PCa). Even though mpMRI has been shown to be very informative for detection of local PCa recurrences, high variability in its application and interpretation remains. Experts from the European Society for Urogenital Radiology (ESUR), the Imaging Committee of the European Association of Urology (ESUI), and several members of the PI-RADS committee developed a unified report system called Prostate Imaging Recurrence Reporting (PI-RR) to measure the risk of local recurrence of PCa in men who have had radical prostatectomy and radiation therapy and are being followed up. The principles of mpMRI that form the basis of PI-RR are well known and are stated in the PI-RADS v.2.1 guidelines, which have proven their diagnostic efficiency. The PI-RR system has the potential to become an important tool for improving communication between specialists involved in the process of PCa diagnosis and treatment, for optimizing treatment strategy in patients with local PCa recurrence, and for improving survival rates in patients with PCa after specialized anticancer treatment.